Linked Data API

Show Search Form

Search Results

1629171
star this property registered interest false more like this
star this property date less than 2023-05-19more like thismore than 2023-05-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Immunotherapy and Transplant Surgery: Cost of Living more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government what steps they are taking to mitigate the impact of the increased cost of living on stem cell transplant and CAR-T therapy recipients. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7973 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-06-01more like thismore than 2023-06-01
unstar this property answer text <p>There are no plans to assess the potential benefits and costs of establishing a patient travel fund for stem cell transplant and CAR-T recipients. NHS England does not provide any specific cost of living support for patients receiving stem cell transplantation, however, trusts can exercise discretion to provide accommodation and/or other support depending on local and individual patient circumstances. The Non-Emergency Patient Transport Services (NEPTS) provide funded transport where it is considered essential to ensuring an individual’s safety, safe mobilisation, condition management or recovery.</p><p>Depending on a patient’s financial circumstances, they may be eligible for financial support with costs via the NHS Low Income Scheme and Healthcare Travel Costs Scheme. Those who do not qualify for NEPTS and need financial help with travel can access the Healthcare Travel Costs Scheme. This is aimed specifically at those with a low income and allows patients to claim for all or part their travel costs should they meet the eligibility criteria.</p><p>We recognise the pressures people are facing with the rising cost of living. Our extensive arrangements to help people afford NHS prescription charges, means that almost 89% of prescription items dispensed in community pharmacies in England are already provided free of charge. For those not exempt from charges, pre-payment certificates can be used to cap costs at just over £2 a week for regular prescriptions.</p><p>People with long-term health conditions or disabilities, including those requiring stem cell transplants, may be entitled to financial support to contribute towards their extra costs such as Personal Independence Payment (PIP). Entitlement to PIP is assessed on the basis of the needs arising from a health condition or disability, rather than the health condition or disability itself.</p><p>The Government does not any specific support to stem cell transplant and CAR-T therapy patients pursuing a safe return to work. However, the Government has a range of initiatives to support disabled people and people with health conditions, including stem cell transplant and CAR-T therapy patients, to start, stay and succeed in work. These include increasing Work Coach and Disability Employment Advisers’ support in Jobcentres, the Work and Health Programme, Intensive Personalised Employment Support, Access to Work grants, Disability Confident, the Information and Advice Service and support in partnership between Department for Work and Pensions and the health system, including Employment Advice in NHS Talking Therapies.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN
HL7974 more like this
HL7976 more like this
star this property question first answered
less than 2023-06-01T13:23:32.56Zmore like thismore than 2023-06-01T13:23:32.56Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1629172
star this property registered interest false more like this
star this property date less than 2023-05-19more like thismore than 2023-05-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Immunotherapy and Transplant Surgery: Travel more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government whether they intend to assess (1) the potential benefit of establishing a patient travel fund for stem cell transplant and CAR-T therapy recipients, and (2) the potential cost to the Treasury. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7974 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-06-01more like thismore than 2023-06-01
unstar this property answer text <p>There are no plans to assess the potential benefits and costs of establishing a patient travel fund for stem cell transplant and CAR-T recipients. NHS England does not provide any specific cost of living support for patients receiving stem cell transplantation, however, trusts can exercise discretion to provide accommodation and/or other support depending on local and individual patient circumstances. The Non-Emergency Patient Transport Services (NEPTS) provide funded transport where it is considered essential to ensuring an individual’s safety, safe mobilisation, condition management or recovery.</p><p>Depending on a patient’s financial circumstances, they may be eligible for financial support with costs via the NHS Low Income Scheme and Healthcare Travel Costs Scheme. Those who do not qualify for NEPTS and need financial help with travel can access the Healthcare Travel Costs Scheme. This is aimed specifically at those with a low income and allows patients to claim for all or part their travel costs should they meet the eligibility criteria.</p><p>We recognise the pressures people are facing with the rising cost of living. Our extensive arrangements to help people afford NHS prescription charges, means that almost 89% of prescription items dispensed in community pharmacies in England are already provided free of charge. For those not exempt from charges, pre-payment certificates can be used to cap costs at just over £2 a week for regular prescriptions.</p><p>People with long-term health conditions or disabilities, including those requiring stem cell transplants, may be entitled to financial support to contribute towards their extra costs such as Personal Independence Payment (PIP). Entitlement to PIP is assessed on the basis of the needs arising from a health condition or disability, rather than the health condition or disability itself.</p><p>The Government does not any specific support to stem cell transplant and CAR-T therapy patients pursuing a safe return to work. However, the Government has a range of initiatives to support disabled people and people with health conditions, including stem cell transplant and CAR-T therapy patients, to start, stay and succeed in work. These include increasing Work Coach and Disability Employment Advisers’ support in Jobcentres, the Work and Health Programme, Intensive Personalised Employment Support, Access to Work grants, Disability Confident, the Information and Advice Service and support in partnership between Department for Work and Pensions and the health system, including Employment Advice in NHS Talking Therapies.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN
HL7973 more like this
HL7976 more like this
star this property question first answered
less than 2023-06-01T13:23:32.847Zmore like thismore than 2023-06-01T13:23:32.847Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1629174
star this property registered interest false more like this
star this property date less than 2023-05-19more like thismore than 2023-05-19
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Stem Cells and Immunotherapy: more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government what steps they are taking to support stem cell transplant and CAR-T therapy patients in pursuing a safe return to work while maintaining protections for their health. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7976 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-06-01more like thismore than 2023-06-01
unstar this property answer text <p>There are no plans to assess the potential benefits and costs of establishing a patient travel fund for stem cell transplant and CAR-T recipients. NHS England does not provide any specific cost of living support for patients receiving stem cell transplantation, however, trusts can exercise discretion to provide accommodation and/or other support depending on local and individual patient circumstances. The Non-Emergency Patient Transport Services (NEPTS) provide funded transport where it is considered essential to ensuring an individual’s safety, safe mobilisation, condition management or recovery.</p><p>Depending on a patient’s financial circumstances, they may be eligible for financial support with costs via the NHS Low Income Scheme and Healthcare Travel Costs Scheme. Those who do not qualify for NEPTS and need financial help with travel can access the Healthcare Travel Costs Scheme. This is aimed specifically at those with a low income and allows patients to claim for all or part their travel costs should they meet the eligibility criteria.</p><p>We recognise the pressures people are facing with the rising cost of living. Our extensive arrangements to help people afford NHS prescription charges, means that almost 89% of prescription items dispensed in community pharmacies in England are already provided free of charge. For those not exempt from charges, pre-payment certificates can be used to cap costs at just over £2 a week for regular prescriptions.</p><p>People with long-term health conditions or disabilities, including those requiring stem cell transplants, may be entitled to financial support to contribute towards their extra costs such as Personal Independence Payment (PIP). Entitlement to PIP is assessed on the basis of the needs arising from a health condition or disability, rather than the health condition or disability itself.</p><p>The Government does not any specific support to stem cell transplant and CAR-T therapy patients pursuing a safe return to work. However, the Government has a range of initiatives to support disabled people and people with health conditions, including stem cell transplant and CAR-T therapy patients, to start, stay and succeed in work. These include increasing Work Coach and Disability Employment Advisers’ support in Jobcentres, the Work and Health Programme, Intensive Personalised Employment Support, Access to Work grants, Disability Confident, the Information and Advice Service and support in partnership between Department for Work and Pensions and the health system, including Employment Advice in NHS Talking Therapies.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN
HL7973 more like this
HL7974 more like this
star this property question first answered
less than 2023-06-01T13:23:32.937Zmore like thismore than 2023-06-01T13:23:32.937Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1330360
star this property registered interest false more like this
star this property date less than 2021-06-07more like thismore than 2021-06-07
star this property answering body
Treasury more like this
star this property answering dept id 14 more like this
star this property answering dept short name Treasury more like this
unstar this property answering dept sort name Treasury more like this
star this property hansard heading Bitcoin: Energy more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government, further to the establishment of the Bitcoin Mining Council, what steps they will take (1) to encourage the use of renewable power and sustainable Bitcoin mining, and (2) to monitor the effectiveness of the Council. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL787 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2021-06-16more like thismore than 2021-06-16
unstar this property answer text The Government has been monitoring developments within the cryptoasset industry, including rising energy usage.<p> </p><p>The Cryptoasset Taskforce, comprising HM Treasury, the Financial Conduct Authority, and the Bank of England, considers the impact of cryptoassets and assesses what, if any, regulation is required in response. The Government stands ready to respond to emerging risks or changes in the market and will continue to monitor developments in cryptoassets.</p><p> </p><p>In November 2020, the Chancellor announced that the UK will implement a green taxonomy – a common framework for determining which activities can be defined as environmentally sustainable – which will improve understanding of the impact of firms’ activities and investments on the environment and support our transition to a sustainable economy. More details on the green taxonomy will be announced in due course.</p>The Government has already taken action to ensure the UK is the world-leading centre for green finance including through announcing an intention to make disclosures aligned with the Taskforce on Climate-related Financial Disclosures (TCFD) fully mandatory across the economy by 2025, making the UK the first country to do so.
star this property answering member printed Lord Agnew of Oulton more like this
star this property grouped question UIN
HL788 more like this
HL789 more like this
star this property question first answered
less than 2021-06-16T10:45:07.947Zmore like thismore than 2021-06-16T10:45:07.947Z
star this property answering member
4689
star this property label Biography information for Lord Agnew of Oulton more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1330361
star this property registered interest false more like this
star this property date less than 2021-06-07more like thismore than 2021-06-07
star this property answering body
Treasury more like this
star this property answering dept id 14 more like this
star this property answering dept short name Treasury more like this
unstar this property answering dept sort name Treasury more like this
star this property hansard heading Cryptocurrencies: Environment Protection more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government whether (1) the Cryptoasset Taskforce, or (2) any government department, collects or collates data on the environmental impact of cryptocurrencies; and if so, when any such data will be published. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL788 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2021-06-16more like thismore than 2021-06-16
unstar this property answer text The Government has been monitoring developments within the cryptoasset industry, including rising energy usage.<p> </p><p>The Cryptoasset Taskforce, comprising HM Treasury, the Financial Conduct Authority, and the Bank of England, considers the impact of cryptoassets and assesses what, if any, regulation is required in response. The Government stands ready to respond to emerging risks or changes in the market and will continue to monitor developments in cryptoassets.</p><p> </p><p>In November 2020, the Chancellor announced that the UK will implement a green taxonomy – a common framework for determining which activities can be defined as environmentally sustainable – which will improve understanding of the impact of firms’ activities and investments on the environment and support our transition to a sustainable economy. More details on the green taxonomy will be announced in due course.</p>The Government has already taken action to ensure the UK is the world-leading centre for green finance including through announcing an intention to make disclosures aligned with the Taskforce on Climate-related Financial Disclosures (TCFD) fully mandatory across the economy by 2025, making the UK the first country to do so.
star this property answering member printed Lord Agnew of Oulton more like this
star this property grouped question UIN
HL787 more like this
HL789 more like this
star this property question first answered
less than 2021-06-16T10:45:08.01Zmore like thismore than 2021-06-16T10:45:08.01Z
star this property answering member
4689
star this property label Biography information for Lord Agnew of Oulton more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1330362
star this property registered interest false more like this
star this property date less than 2021-06-07more like thismore than 2021-06-07
star this property answering body
Treasury more like this
star this property answering dept id 14 more like this
star this property answering dept short name Treasury more like this
unstar this property answering dept sort name Treasury more like this
star this property hansard heading Cryptocurrencies: Environment Protection more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty's Government what assessment they have made of the level of energy use in the mining of Bitcoin, as identified by the Cambridge Bitcoin Electricity Consumption Index; and what steps they will take to address the environmental harms of cryptocurrencies. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL789 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2021-06-16more like thismore than 2021-06-16
unstar this property answer text The Government has been monitoring developments within the cryptoasset industry, including rising energy usage.<p> </p><p>The Cryptoasset Taskforce, comprising HM Treasury, the Financial Conduct Authority, and the Bank of England, considers the impact of cryptoassets and assesses what, if any, regulation is required in response. The Government stands ready to respond to emerging risks or changes in the market and will continue to monitor developments in cryptoassets.</p><p> </p><p>In November 2020, the Chancellor announced that the UK will implement a green taxonomy – a common framework for determining which activities can be defined as environmentally sustainable – which will improve understanding of the impact of firms’ activities and investments on the environment and support our transition to a sustainable economy. More details on the green taxonomy will be announced in due course.</p>The Government has already taken action to ensure the UK is the world-leading centre for green finance including through announcing an intention to make disclosures aligned with the Taskforce on Climate-related Financial Disclosures (TCFD) fully mandatory across the economy by 2025, making the UK the first country to do so.
star this property answering member printed Lord Agnew of Oulton more like this
star this property grouped question UIN
HL787 more like this
HL788 more like this
star this property question first answered
less than 2021-06-16T10:45:08.087Zmore like thismore than 2021-06-16T10:45:08.087Z
star this property answering member
4689
star this property label Biography information for Lord Agnew of Oulton more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1626821
star this property registered interest false more like this
star this property date less than 2023-05-10more like thismore than 2023-05-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cancer Drugs Fund more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government what discussions they have had with patient groups on the updates to the NICE health technology evaluations manual, and in particular (1) treatments at the end of a Cancer Drugs Fund access agreement no longer being assessed against the criteria supporting their original recommendation, and (2) the replacement of the end of life criteria with a severity modifier. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7742 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-05-16more like thismore than 2023-05-16
unstar this property answer text <p>The Department has had no discussions and has made no current plans. The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses and engaged with a wide range of stakeholders during the development of its updated manual for health technology evaluations, including on the severity modifier. Patient groups were directly involved in the methods review in the working group, task and finish groups and in two public consultations. Additionally, NICE engaged separately with industry and patient groups on the impact of the changes to it methods and processes for medicines currently in the Cancer Drugs Fund.</p><p>NICE also works closely with patient groups and other stakeholders in the development of its guidance on individual technologies. In 2022/23, 89% of NICE’s final recommendations on cancer drugs were positive, including all of the cancer medicines appraised using NICE’s updated methods and processes. No cancer medicines have completed their exit from the CDF using NICE’s updated methods and processes. However, NICE has released positive final draft guidance for the first, which treats a blood cancer.</p><p>If NICE determines at the end of a managed access period that a technology is not a good use of National Health Service resources, then people already having treatment may continue until they and their NHS clinician consider it appropriate to stop.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN HL7743 more like this
star this property question first answered
less than 2023-05-16T15:29:46.2Zmore like thismore than 2023-05-16T15:29:46.2Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1626822
star this property registered interest false more like this
star this property date less than 2023-05-10more like thismore than 2023-05-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cancer Drugs Fund more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government what plans they have to work with patient groups, including on blood cancer, to allow continued access to treatments at the end of a Cancer Drugs Fund access agreement that meet the original end of life criteria but not the new severity modifier criteria following updates to the NICE health technology evaluations manual. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7743 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-05-16more like thismore than 2023-05-16
unstar this property answer text <p>The Department has had no discussions and has made no current plans. The National Institute for Health and Care Excellence (NICE) is responsible for developing the methods and processes it uses and engaged with a wide range of stakeholders during the development of its updated manual for health technology evaluations, including on the severity modifier. Patient groups were directly involved in the methods review in the working group, task and finish groups and in two public consultations. Additionally, NICE engaged separately with industry and patient groups on the impact of the changes to it methods and processes for medicines currently in the Cancer Drugs Fund.</p><p>NICE also works closely with patient groups and other stakeholders in the development of its guidance on individual technologies. In 2022/23, 89% of NICE’s final recommendations on cancer drugs were positive, including all of the cancer medicines appraised using NICE’s updated methods and processes. No cancer medicines have completed their exit from the CDF using NICE’s updated methods and processes. However, NICE has released positive final draft guidance for the first, which treats a blood cancer.</p><p>If NICE determines at the end of a managed access period that a technology is not a good use of National Health Service resources, then people already having treatment may continue until they and their NHS clinician consider it appropriate to stop.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN HL7742 more like this
star this property question first answered
less than 2023-05-16T15:29:46.277Zmore like thismore than 2023-05-16T15:29:46.277Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1626819
star this property registered interest false more like this
star this property date less than 2023-05-10more like thismore than 2023-05-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cancer Drugs Fund more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government what assessment they have made of the impact of updates to the NICE health technology evaluations manual on access to treatments at the end of a Cancer Drugs Fund access agreement. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7740 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-05-19more like thismore than 2023-05-19
unstar this property answer text <p>The National Institute for Health and Care Excellence (NICE) published its updated manual for health technology evaluations in January 2022 and has introduced a number of changes to make its methods and processes fairer, faster and more consistent. This includes the introduction of a broader severity modifier in place of the end of life modifier. Analysis carried out by NICE in the development of the modifier indicates that the vast majority of cancer medicines, including for blood cancers, that would be eligible for the end of life modifier would also be eligible for a weighting under the severity modifier.</p><p>In 2022/23, 89% of NICE’s final recommendations on cancer drugs were positive, including all of the cancer medicines appraised using NICE’s updated methods and processes. No cancer medicines have completed their exit from the Cancer Drugs Fund using NICE’s updated methods and processes. However, NICE has released positive final draft guidance for the first, which treats a blood cancer.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN HL7741 more like this
star this property question first answered
less than 2023-05-19T12:01:45.187Zmore like thismore than 2023-05-19T12:01:45.187Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter
1626820
star this property registered interest false more like this
star this property date less than 2023-05-10more like thismore than 2023-05-10
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
unstar this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cancer Drugs Fund more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask His Majesty's Government what assessment they have made of the impact on patients with multiple myeloma of (1) updates to the NICE health technology evaluations manual, and (2) the forthcoming end of Cancer Drugs Fund access agreements for treatments. more like this
star this property tabling member printed
Lord Mendelsohn more like this
star this property uin HL7741 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2023-05-19more like thismore than 2023-05-19
unstar this property answer text <p>The National Institute for Health and Care Excellence (NICE) published its updated manual for health technology evaluations in January 2022 and has introduced a number of changes to make its methods and processes fairer, faster and more consistent. This includes the introduction of a broader severity modifier in place of the end of life modifier. Analysis carried out by NICE in the development of the modifier indicates that the vast majority of cancer medicines, including for blood cancers, that would be eligible for the end of life modifier would also be eligible for a weighting under the severity modifier.</p><p>In 2022/23, 89% of NICE’s final recommendations on cancer drugs were positive, including all of the cancer medicines appraised using NICE’s updated methods and processes. No cancer medicines have completed their exit from the Cancer Drugs Fund using NICE’s updated methods and processes. However, NICE has released positive final draft guidance for the first, which treats a blood cancer.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN HL7740 more like this
star this property question first answered
less than 2023-05-19T12:01:45.24Zmore like thismore than 2023-05-19T12:01:45.24Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
4286
unstar this property label Biography information for Lord Mendelsohn remove filter